Positron Emission Tomography (PET) Radiotracer Market Forecast Signals New Revenue Opportunities Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
The positron emission tomography (PET) radiotracer market has witnessed significant growth over recent years, driven by advancements in medical imaging and increasing demand for precise diagnostic tools. As healthcare providers continue to adopt innovative technologies, this market is positioned for substantial expansion in the coming years. Let’s explore the current market size, key growth drivers, major players, emerging trends, and regional dynamics shaping the future of the PET radiotracer sector.
Market Size and Growth Outlook for the PET Radiotracer Market
The PET radiotracer market has expanded steadily, with its size rising from $2.54 billion in 2025 to $2.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. This growth stems from factors such as increasing cancer diagnosis rates, the proliferation of nuclear medicine facilities, widespread use of FDG-based imaging, availability of cyclotron infrastructure, and the broader expansion of diagnostic imaging services. Looking ahead, the market is forecasted to reach $3.95 billion by 2030, maintaining the same CAGR of 9.2%. Drivers during this period will include rising demand for precision diagnostics, growing investments in radiopharmaceutical research and development, expanded applications in theranostics, and greater adoption of PET imaging in neurology and cardiology. Additionally, the market will benefit from increasing regulatory approvals for new tracers, the development of target-specific radiotracers, and an enhanced focus on personalized nuclear medicine.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp
Factors Contributing to the Surge in PET Radiotracer Demand
One of the prominent factors fueling market growth is the rising prevalence of infectious diseases worldwide. These diseases, caused by bacteria, viruses, fungi, or parasites, are becoming more common due to influences such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior that facilitate pathogen spread. PET radiotracers assist in managing infectious diseases by visualizing metabolic activity and inflammation, which helps detect infections, monitor treatment effectiveness, and differentiate between infectious and non-infectious conditions, ultimately improving patient care.
For instance, a report released by the UK Health Security Agency in February 2024 indicated that tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases recorded compared to 4,380 in 2022. This rise in infectious diseases like TB underscores the growing need for PET radiotracers in clinical diagnostics, further driving the market’s expansion.
Access The Complete Positron Emission Tomography (PET) Radiotracer Market Report:
Breakdown of PET Radiotracer Market Segments
The PET radiotracer market is divided into key segments based on radiotracer type, application, and end-user. By radiotracer type, the market includes F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), and other radiotracer varieties. The F-18 category further comprises F-18 FDG, F-18 Fluoroethyltyrosine (FET), and F-18 Florbetapir, mainly used for amyloid PET imaging. Ga-68 subtypes include Ga-68 Dotatate for neuroendocrine tumor imaging, Ga-68 PSMA for prostate-specific membrane antigen imaging, and Ga-68 FAPI for fibroblast activation protein inhibitor imaging. Other radiotracer types cover isotopes like C-11, N-13, O-15, Rb-82, and I-124.
Regarding applications, PET radiotracers are utilized in cancer diagnostics, heart disease, gastrointestinal and endocrine disorders, neurological conditions, and other medical uses. The primary end-users of these radiotracers are hospitals, diagnostic centers, and other healthcare facilities.
Innovations and Trends Driving the PET Radiotracer Market
Leading companies in the PET radiotracer field are investing heavily in developing innovative diagnostic solutions to improve cancer detection and patient outcomes. PET imaging agents, which are radioactive substances used during scans to visualize biological processes, are at the forefront of this development. For example, in March 2023, IsoLogic Innovative Radiopharmaceuticals, based in Canada, introduced Illuccix (also called the Ga-68 Gozetotide Preparation Kit or PSMA-11) for prostate cancer imaging. This agent helps physicians detect metastatic prostate cancer and make informed treatment decisions, particularly useful for patients suspected of metastasis or recurrence indicated by elevated serum prostate-specific antigen (PSA) levels.
Another important trend is the ongoing development and approval of novel, target-specific radiotracers that expand PET imaging applications beyond traditional uses. This includes the adoption of new isotopes and the growth of personalized nuclear medicine, leveraging short-half-life radiotracers to tailor diagnostics and therapies to individual patient needs.
Competitive Landscape of the PET Radiotracer Market
Several prominent companies drive competition and innovation in this market. These include Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., IsoLogic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., and Piramal Imaging. These companies are focused on expanding their product portfolios, pursuing regulatory approvals, and enhancing production capabilities to meet rising market demand.
Geographical Insights Highlighting Regional Market Dynamics
In 2025, North America led the PET radiotracer market in terms of revenue, benefiting from advanced healthcare infrastructure and high adoption rates of nuclear medicine technologies. However, the Asia-Pacific region is expected to experience the fastest growth throughout the forecast period. This is driven by increasing healthcare investments, expanding diagnostic services, and growing awareness of precision medicine in countries across Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Overall, the PET radiotracer market is set for robust growth fueled by technological advancements, expanding applications in various medical fields, and rising demand for accurate diagnostics worldwide.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
